CN103588758A - 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 - Google Patents
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 Download PDFInfo
- Publication number
- CN103588758A CN103588758A CN201310540990.3A CN201310540990A CN103588758A CN 103588758 A CN103588758 A CN 103588758A CN 201310540990 A CN201310540990 A CN 201310540990A CN 103588758 A CN103588758 A CN 103588758A
- Authority
- CN
- China
- Prior art keywords
- nitroimidazole
- preparation
- ethyl
- fat
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004957 nitroimidazoles Chemical class 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 51
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical group C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 title abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 abstract description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000005249 lung adenocarcinoma Diseases 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 62
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 41
- 150000001875 compounds Chemical class 0.000 description 21
- 239000003814 drug Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- -1 glyoxaline compound Chemical class 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 208000006503 Amebic Liver Abscess Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010063741 Hepatic amoebiasis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- OFNBVRGBYQLGPG-FPYGCLRLSA-N [O-][N+](c1cnc(/C=C/c(cc2)ccc2Br)[n]1CCOC(c1ccc2OCCOc2c1)=O)=O Chemical compound [O-][N+](c1cnc(/C=C/c(cc2)ccc2Br)[n]1CCOC(c1ccc2OCCOc2c1)=O)=O OFNBVRGBYQLGPG-FPYGCLRLSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成,其特征是它有如下通式:
Description
技术领域
本发明涉及一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用。
背景技术
咪唑衍生物,它广泛用于厌氧菌感染的治疗,如用于治疗肠道和肠外阿米巴病(如阿米巴肝脓肿、胸膜阿米巴病等),阴道滴虫病、小袋虫病等。近年来研究发现咪唑类化合物具有多种生物活性,尤其作为抗癌药物显示了广阔的应用前景,但存在药动学性质差、不良反应明显等特点,对其结构进行有效的改造以获得高效、低毒的咪唑类抗癌药物已成为当前药物化学领域研究的热点之一。
1,4-苯并二噁烷中含有2个氧原子,易产生多种非共价键相互作用,如氢键与金属离子配位等,据文献报道这两个氧原子对配体-受体的紧密结合起重要作用,这对提高药物的靶向性有着重要意义,具有较大的发展潜力。此外,作为重要的活性中间体,1,4-苯并二噁烷是一种广泛存在于自然界的药效基团,具有抗癌、抗真菌、抗精神病等多种生理活性。
根据以上分析结果,本发明将1,4-苯并二噁烷引入到咪唑类衍生物中,设计合成了一系列结构新颖的含1,4-苯并二噁烷骨架的硝基咪唑衍生物,期望具有更好的生物活性、更高的选择性、更低的毒性、更长或更短的残效期等.
发明内容
本发明的目的在于提供一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用。
本发明的技术方案如下:
1.一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成,其特征是它有如下通式:
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的制法,它由下列步骤组成:
步骤1 在反应容器中依次加入化合物2、有机溶剂,在适当条件下搅拌,溶解,然后加入适量的对甲基苯磺酰氯,最后滴加适量的三乙胺做催化剂。在一定的温度下反应一段时间(TLC监测反应),在反应结束后,直接过滤获得粗产品,粗产品再采用适当有机溶剂重结晶或经柱层析提纯获得目标化合物3。
步骤2 将化合物3、有机酸按一定比例依次加入到含有一定体积有机溶剂的容器中,在适当条件下搅拌,溶解,再加入弱碱做催化剂。回流搅拌反应一段时间(TLC监测反应),反应结束后,将反应液倒入烧杯中,加入冰水,有固体析出,过滤、洗涤,获得粗产品,将粗产品再采用适当溶剂重结晶或经柱层析提纯获得目标化合产物4。
具体实施方式
实施例一:(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂(3)的制备
在搅拌条件下,向50mL圆底烧瓶中依次加入(E)-2-(2-苯乙烯基-5-硝基咪唑)乙醇(2.59g,10mmol)、20mL的CH2Cl2、对甲基苯磺酰氯(1.90g,10mmol)以及10mL的三乙胺,室温下搅拌反应7小时后(TLC检测反应),过滤、洗涤干燥得到粗产物,然后将粗产物用乙醇中进行重结晶,得到白色晶体目标化合物。产率83.5%.m.p.164~167℃;1H NMR(DMSO-d6,300MHzδppm)δ:8.01(s,1H,C-CH-N),7.91~7.74(m,4H,Ph-H),7.34~7.28(m,5H,Ph-H),7.04(d,J=6.4Hz,2H,C-CH-CH),4.49(d,2H,J=5.7Hz,C-CH2-C),4.22(s,2H,C-CH2-C),2.44(s,3H,CH3-C).
实施例二:(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4u)的制备
将上述白色产物(2.06g,5mmol)加入含有15mL DMF的25mL圆底烧瓶中,搅拌至溶解,再加入1,4-苯并二噁烷-6-羧酸(1.7g,7.5mmol),溶解后加入K2CO3(5mmol,0.69g)做催化剂。回流搅拌下反应4小时后(TLC检测反应),静置待其冷却后,将反应物加入到20mL冰水中,析出的固体过滤烘干后用丙酮和无水乙醇溶解重结晶。产率62.7%.m.p.173~175℃;1H NMR(DMSO-d6,300MHz,δppm):4.23(s,2H,O-CH2-C),4.36(s,2H,C-CH2-O),4.67(s,2H,N-CH2-C),5.01(s,2H,C-CH2-O),6.67(d,J=4.5Hz,1H,C-CH-C),7.23~7.35(m, 6H,C-CH-C,Ph-H),7.45~7.55(m,3H,Ph-H),8.21(s,1H,N-CH).
实施例三:(E)-2-(2-(2-氟苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4a)的制备
制备方法同实施例二以(E)-2-(2-(2-氟苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率65.2%.m.p.176~177℃;1H NMR(DMSO-d6,300MHz,δppm):4.13(s,4H,O-CH2-CH2-O),4.58(t,J=6.2Hz,2H,N-CH2-C),5.02(s,2H,C-CH2-O),6.50(t,J=3.6Hz,1H,C-CH-C),6.91(d,J=8.4Hz,1H,C-CH-C),7.05~7.31(m,5H,Ph-H),7.79~7.95(m,2H,Ph-H),8.23(s,1H,N-CH).
实施例四:(E)-2-(2-(3-氟苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4b)的制备
制备方法同实施例二以(E)-2-(2-(3-氟苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率58.0%.m.p.198~200℃;1H NMR(DMSO-d6,300MHz,δppm):4.12(d,J=5.3Hz,4H,O-CH2-CH2-O),4.61(s,2H,N-CH2-C),5.01(s,2H,C-CH2-O),6.58(d,J=8.1Hz,1H,C-CH-C),7.16~7.32(m,3H,C-CH-C,Ph-H),7.37~7.55(m,3H,Ph-H),7.59~7.75(m,2H,Ph-H),8.24(s,1H,N-CH).
实施例五:(E)-2-(2-(4-氟苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4c)的制备
制备方法同实施例二以(E)-2-(2-(4-氟苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率64.1%.m.p.201~203℃;1H NMR(DMSO-d6,300MHz,δppm):4.09(s,4H,O-CH2-CH2-O),4.60(s,2H,N-CH2-C),5.00(s,2H,C-CH2-O),6.57(d,J=7.4Hz,1H,C-CH-C),7.14~7.47(m,4H,C-CH-C,Ph-H),7.42~7.66(m,2H,Ph-H),7.70~7.94(m,2H,Ph-H),8.23(s,1H,N-CH).
实施例六:(E)-2-(2-(2-氯苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4d)的制备
制备方法同实施例二以(E)-2-(2-(2-氯苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率65.3%.m.p.181~182℃;1H NMR(DMSO-d6,300MHz,δppm):4.07~4.18(m,4H,O-CH2-CH2),4.61(s,2H,N-CH2-C),5.01(s,2H,C-CH2-O),6.59(d,J=7.5Hz,1H,C-CH-C),7.16~7.32(m,4H,C-CH-C,Ph-H),7.32~7.43(m,2H,Ph-H),7.50(t,J=4.9Hz,2H,Ph-H),8.24(s,1H,N-CH).
实施例七:(E)-2-(2-(3-氯苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4e)的制备
制备方法同实施例二以(E)-2-(2-(3-氯苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率59.2%.m.p.190~192℃;1H NMR(DMSO-d6,300MHz,δppm):4.06(s,2H,O-CH2-C),4.13~4.17(m,2H,C-CH2-O),4.57(s,2H,N-CH2-C),5.03(s,2H,C-CH2-O),6.54(d,J=7.3Hz,1H,C-CH-C),7.19~7.35(m,4H,C-CH-C,Ph-H),7.39(d,J=5.7Hz,3H,Ph-H),7.69(t,J=6.7Hz,1H,Ph-H),8.23(s,1H,N-CH).
实施例八:(E)-2-(2-(4-氯苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4f)的制备
制备方法同实施例二以(E)-2-(2-(4-氯苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率61.8%.m.p.206~208℃;1H NMR(DMSO-d6,300MHz,δppm):4.07(s,2H,O-CH2-C),4.17(s,2H,O-CH2-C),4.59(s,2H,N-CH2-C),4.99(s,2H,C-CH2-O),6.58(d,J=7.1Hz,1H,C-CH-C),7.22(t,J=8.7Hz,2H,C-CH-C,Ph-H),7.45(t,J=6.1Hz,3H,Ph-H),7.70(t,J=6.3Hz,3H,Ph-H),8.24(s,1H,N-CH).
实施例九:(E)-2-(2-(2-溴苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6- 羧酸脂(4g)的制备
制备方法同实施例二以(E)-2-(2-(2-溴苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率65.1%.m.p.194~196℃;1H NMR(DMSO-d6,300MHz,δppm):4.09(s,2H,O-CH2-C),4.18(s,2H,O-CH2-C),4.59(s,2H,N-CH2-C),5.01(s,2H,C-CH2-O),6.67(d,J=7.0Hz,1H,C-CH-C),7.21(t,J=8.7Hz,2H,C-CH-C,Ph-H),7.32~7.48(m,3H,Ph-H),7.64~7.85(m,3H,Ph-H),8.25(s,1H,N-CH).
实施例十:(E)-2-(2-(3-溴苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4h)的制备
制备方法同实施例二以(E)-2-(2-(3-溴苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率66.5%.m.p.193~195℃;1H NMR(DMSO-d6,300MHz,δppm):4.12(s,4H,O-CH2-CH2-O),4.53(s,2H,N-CH2-C),5.03(s,2H,C-CH2-O),6.59(d,J=7.4Hz,1H,C-CH-C),7.31~7.47(m,4H,C-CH-C,Ph-H),7.52~7.64(m,2H,Ph-H),7.75~7.81(m,2H,Ph-H),8.25(s,1H,N-CH).
实施例十一:(E)-2-(2-(4-溴苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4i)的制备
制备方法同实施例二以(E)-2-(2-(4-溴苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率57.4%.m.p.205~207℃;1H NMR(DMSO-d6,300MHz,δppm):4.24(s,4H,O-CH2-CH2-O),4.60(s,2H,N-CH2-C),5.00(s,2H,C-CH2-O),6.60(d,J=8.4Hz,1H,C-CH-C),7.15~7.29(m,2H,C-CH-C,Ph-H),7.44~7.71(m,6H,Ph-H),8.23(s,1H,N-CH).
实施例十二:(E)-2-(2-(2-甲基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4j)的制备
制备方法同实施例二以(E)-2-(2-(2-甲基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率72.6%.m.p.172~174℃;1H NMR(DMSO-d6,300MHz,δppm):2.50(s,3H,-CH3),4.13(d,J=6.0Hz,4H,O-CH2-CH2-O),4.63(s,2H,N-CH2-C),4.90(s,2H,C-CH2-O),6.64(d,J=7.3Hz,1H,C-CH-C),7.17~7.46(m,7H,C-CH-C,Ph-H),7.84(d,J=5.7Hz,1H,Ph-H),8.27(s,1H,N-CH).
实施例十三:(E)-2-(2-(3-甲基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4k)的制备
制备方法同实施例二以(E)-2-(2-(3-甲基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率71.2%.m.p.173~175℃;1H NMR(DMSO-d6,300MHz,δppm):2.47(s,3H,-CH3),4.15(s,4H,O-CH2-CH2-O),4.61(d,J=4.6Hz,2H,N-CH2-C),4.92(t,J=5.3Hz,2H,C-CH2-O),6.89(d,J=7.3Hz,1H,C-CH-C),7.05~7.34(m,2H,C-CH-C,Ph-H),7.34~7.86(m,6H,Ph-H),8.24(s,1H,N-CH).
实施例十四:(E)-2-(2-(4-甲基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(41)的制备
制备方法同实施例二以(E)-2-(2-(4-甲基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率71.4%.m.p.183~185℃;1H NMR(DMSO-d6,300MHz,δppm):2.49(s,3H,-CH3),4.12(s,4H,O-CH2-CH2-O),4.58(t,J=4.2Hz,2H,N-CH2-C),4.87(t,J=8.4Hz,2H,C-CH2-O),6.57(d,J=5.3Hz,1H,C-CH-C),6.88~7.15(m,2H,C-CH-C,Ph-H),7.34~7.48(m,4H,Ph-H),7.82~7.98(m,2H,Ph-H),8.27(s,1H,N-CH).
实施例十五:(E)-2-(2-(2-硝基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁 烷-6-羧酸脂(4m)的制备
制备方法同实施例二以(E)-2-(2-(2-硝基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率64.4%.m.p.193~194℃;1H NMR(DMSO-d6,300MHz,δppm):3.37(s,2H,O-CH2-CH2),4.02(m,2H,O-CH2-CH2),4.48(d,J=6.3Hz,2H,N-CH2-C),5.04(s,2H,C-CH2-O),6.84(d,J=5.4Hz,1H,C-CH-C),7.27~7.49(m,4H,C-CH-C,Ph-H),7.88~8.35(m,4H,Ph-H N-CH),8.47(s,1H,Ph-H).
实施例十六:(E)-2-(2-(3-硝基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4n)的制备
制备方法同实施例二以(E)-2-(2-(3-硝基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率58.2%.m.p.195~197℃;1H NMR(DMSO-d6,300MHz,δppm):3.96~4.15(m,4H,O-CH2-CH2),4.64(s,2H,N-CH2-C),5.03(s,2H,C-CH2-O),6.57(d,J=6.5Hz,1H,C-CH-C),7.17~7.28(m,2H,C-CH-C,Ph-H),7.61~7.83(m,3H,Ph-H),8.30~8.56(m,3H,Ph-H N-CH),8.58(s,1H,Ph-H).
实施例十七:(E)-2-(2-(4-硝基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4o)的制备
制备方法同实施例二以(E)-2-(2-(4-硝基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率60.1%.m.p.201~203℃;1H NMR(DMSO-d6,300MHz,δppm):3.98~4.18(m,4H,O-CH2-CH2),4.57(s,2H,N-CH2-C),5.01(s,2H,C-CH2-O),6.63(d,J=5.4Hz,1H,C-CH-C),7.07~7.19(m,2H,C-CH-C,Ph-H),7.43~7.54(m,4H,Ph-H),8.27~8.46(m,2H,Ph-H N-CH),8.42(s,1H,Ph-H).
实施例十八:(E)-2-(2-(2-甲氧基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4p)的制备
制备方法同实施例二以(E)-2-(2-(2-甲氧基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率64.3%.m.p.178~179℃;1H NMR(DMSO-d6,300MHz,δppm):3.77(s,3H,C-OCH3),4.07~4.09(m,2H,O-CH2-C),4.17~4.20(m,2H,C-CH2-O),4.60(t,J=7.2Hz,2H,N-CH2-C),5.00(t,J=4.8Hz,2H,C-CH2-O),6.56(d,J=3.9Hz,1H,C-CH-C),6.94~6.97(m,1H,C-CH-C),7.22~7.33(m,5H,Ph-H),7.43(d,J=8.2Hz,1H,Ph-H),7.69(d,J=7.4Hz,1H,Ph-H),8.23(s,1H,N-CH).
实施例十九:(E)-2-(2-(3-甲氧基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4q)的制备
制备方法同实施例二以(E)-2-(2-(3-甲氧基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂酯,得到黄色目标化合物。产率61.3%.m.p.176~178℃;1H NMR(DMSO-d6,300MHz,δppm):3.76(s,3H,C-OCH3),4.11(s,4H,O-CH2-CH2-O),4.55(s,2H,N-CH2-C),4.98(s,2H,C-CH2-O),6.49(t,J=7.2Hz,1H,C-CH-C),6.92(t,J=8.4Hz,2H,C-CH-C,Ph-H),7.1(d,J=5.22Hz,1H,Ph-H),7.32~7.44(m,4H,Ph-H),7.70(d,J=4.5Hz,1H,Ph-H),8.23(s,1H,N-CH).
实施例二十:(E)-2-(2-(4-甲氧基苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4r)的制备
制备方法同实施例二以(E)-2-(2-(4-甲氧基苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率65.1%.m.p.183~185℃;1H NMR(DMSO-d6,300MHz,δppm):3.59(s,3H,C-OCH3),4.13(s,4H,O-CH2-CH2-O),4.65(s,2H,N-CH2-C),4.78(s,2H,C-CH2-O),6.53(d,J=4.3Hz,1H,C-CH-C),7.03(t,J=4.4Hz,2H,C-CH-C,Ph-H),7.22~7.44(m,5H,Ph-H),7.77(d,J=6.8Hz,1H,Ph-H),8.22(s,1H,N-CH).
实施例二十一:(E)-2-(2-(2-氯-6-氟苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4] 二噁烷-6-羧酸脂(4s)的制备
制备方法同实施例二以(E)-2-(2-(2-氯-6-氟苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率54.1%.m.p.184~186℃;1H NMR(DMSO-d6,300MHz,δppm):4.04~4.24(m,4H,O-CH2-CH2),4.61(s,2H,N-CH2-C),4.98(s,2H,C-CH2-O),6.57(t,J=6.9Hz,1H,C-CH-C),6.90(d,J=4.3Hz,1H,C-CH-C),7.0(d,J=7.83Hz,1H,Ph-H),7.26~7.46(m,4H,C-CH-C,Ph-H),7.85(d,J=5.4Hz,1H,Ph-H),8.27(s,1H,N-CH).
实施例二十二:(E)-2-(2-(2,4-二氯苯乙烯基)-5-硝基咪唑)乙基-2,3-二氢苯并[1,4]二噁烷-6-羧酸脂(4t)的制备
制备方法同实施例二以(E)-2-(2-(2,4-二氯苯乙烯基)-5-硝基咪唑)乙基-4-甲基苯磺酸脂替代(E)-2-(2-苯乙烯基-5-硝基咪唑)乙基-4-甲基苯磺酸脂,得到黄色目标化合物。产率63.5%.m.p.190~192℃;1H NMR(DMSO-d6,300MHz,δppm):4.37(s,4H,O-CH2-CH2-O),4.62(d,J=5.3Hz,2H,N-CH2-C),5.02(s,2H,C-CH2-O),6.58(d,J=7.4Hz,1H,C-CH-C),7.13~7.24(m,2H,C-CH-C,Ph-H),7.53~7.72(m,6H,Ph-H),8.21(s,1H,N-CH).
实例二十三:一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的体外抗癌活性研 究进展
采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法来测定含1,4-苯并二噁烷骨架的硝基咪唑衍生物对人肺腺癌细胞系(A549)、人宫颈癌细胞系(HELA)、人类星形胶质细胞瘤细胞系(U251)和人肝癌细胞系(HEPG2)的抑制率达到50%时的药物浓度(half maximal inhibitory concentration,IC50)。
(1)培养液的配制:DMEM(基础培养基)89%,胎牛血清10%,青霉素链霉素溶液(10000IU/mL,10000μg/mL)1%。
(2)四种贴壁癌细胞的培养:利用上述培养液(培养液体积约为培养瓶容量的1/10),在37℃、5%CO2培养箱中培养,根据癌细胞的生长状态判断传代时间。
(3)不同浓度药物的配制:利用三蒸水(少量DMSO助溶)配制储备液,加药后的每孔细胞悬液中DMSO的终浓度一般不超过0.05%-0.1%;用三蒸水把储备液稀释至六个浓度梯度(10μg/mL,2μg/mL,0.4μg/mL,0.08μg/mL,0.016μg/mL,0.003μg/mL);保存于-20℃冰箱中备用。
(4)细胞孵育:取对数生长期肿瘤细胞,调细胞悬液浓度为1-1.5×105/mL,混匀后加入96孔培养板中(100μL/孔),在37℃,5%CO2培养箱中培养24h。
(5)加药:将稀释好的不同浓度梯度的药物分别加入到96孔培养板中,每个浓度梯度设3个平孔,继续培养48h。实验分为实验组(培养液、细胞、药物)、对照组(培养液和细胞)和空白组(只有培养液)。
(6)存活细胞检测:在培养了48h后的96孔板中,加MTT(5mg/mL)10μL/孔;在37℃放置4h后,移除上清液,加DMSO150μL/孔,振荡至formazan结晶全部溶解;利用自动酶标仪在570nm波长处检测各孔的光密度(OD值)。
抑制率的计算:
生长抑制率=(1-存活率)×100%=[1-(OD实验-OD空白)/(OD对照-OD空白)]×100%(OD实验表示实验组的平均光密度,OD对照表示对照组的平均光密度,OD空白表示空白组的平均光密度)。
根据药物浓度-细胞生长抑制率的标准曲线,求其IC50。
Claims (1)
1.一类含4-苯并二噁烷骨架的硝基咪唑衍生物的合成,其特征是它有如下通式:
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的制法,它由下列步骤组成:
步骤1在反应容器中依次加入化合物2、有机溶剂,在适当条件下搅拌,溶解,然后加入适量的对甲基苯磺酰氯,最后滴加适量的三乙胺做催化剂。在一定的温度下反应一段时间(TLC监测反应),在反应结束后,直接过滤获得粗产品,粗产品再采用适当有机溶剂重结晶或经柱层析提纯获得目标化合物3。
步骤2将化合物3、有机酸按一定比例依次加入到含有一定体积有机溶剂的容器中,在适当条件下搅拌,溶解,再加入弱碱做催化剂。回流搅拌反应一段时间(TLC监测反应),反应结束后,将反应液倒入烧杯中,加入冰水,有固体析出,过滤、洗涤,获得粗产品,将粗产品再采用适当溶剂重结晶或经柱层析提纯获得目标化合产物4。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310540990.3A CN103588758A (zh) | 2013-11-04 | 2013-11-04 | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310540990.3A CN103588758A (zh) | 2013-11-04 | 2013-11-04 | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103588758A true CN103588758A (zh) | 2014-02-19 |
Family
ID=50079110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310540990.3A Pending CN103588758A (zh) | 2013-11-04 | 2013-11-04 | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103588758A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104402864A (zh) * | 2014-10-21 | 2015-03-11 | 南京大学 | 一类抑制端粒酶活性的喹啉咪唑衍生物的合成与生物活性评价 |
CN104447712A (zh) * | 2014-10-21 | 2015-03-25 | 南京大学 | 一类含1,4-苯并二噁烷骨架的2-苯乙烯基-5-硝基咪唑衍生物的合成及生物活性评价 |
WO2017205622A1 (en) * | 2016-05-25 | 2017-11-30 | Savant Neglected Diseases, Llc | Method of making benznidazole |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015500A1 (en) * | 1997-09-05 | 1999-04-01 | Glaxo Group Limited | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
CN1348370A (zh) * | 1999-04-15 | 2002-05-08 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
CN1688550A (zh) * | 2002-08-27 | 2005-10-26 | 阿斯利康(瑞典)有限公司 | 作为金属蛋白酶mmp12抑制剂的2,5-二氧代咪唑烷-4-基乙酰胺及类似物 |
WO2007002559A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
WO2009067621A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
-
2013
- 2013-11-04 CN CN201310540990.3A patent/CN103588758A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015500A1 (en) * | 1997-09-05 | 1999-04-01 | Glaxo Group Limited | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
CN1348370A (zh) * | 1999-04-15 | 2002-05-08 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
CN1688550A (zh) * | 2002-08-27 | 2005-10-26 | 阿斯利康(瑞典)有限公司 | 作为金属蛋白酶mmp12抑制剂的2,5-二氧代咪唑烷-4-基乙酰胺及类似物 |
WO2007002559A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
WO2009067621A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
Non-Patent Citations (4)
Title |
---|
XIAO MIN ZHANG 等: "Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
YA-PING HOU 等: "Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
ZHONG CHANG WANG等: "Potentiating 1-(2-hydroxypropyl)-2-styryl-5-nitroimidazole derivatives against antibacterial agents: Design, synthesis and biology analysis", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
伟尧 等: "硝基咪唑衍生物作为尿素酶抑制剂的分子对接研究", 《扬州大学学报(农业与生命科学版)》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104402864A (zh) * | 2014-10-21 | 2015-03-11 | 南京大学 | 一类抑制端粒酶活性的喹啉咪唑衍生物的合成与生物活性评价 |
CN104447712A (zh) * | 2014-10-21 | 2015-03-25 | 南京大学 | 一类含1,4-苯并二噁烷骨架的2-苯乙烯基-5-硝基咪唑衍生物的合成及生物活性评价 |
WO2017205622A1 (en) * | 2016-05-25 | 2017-11-30 | Savant Neglected Diseases, Llc | Method of making benznidazole |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106749317A (zh) | 一种氮杂环噻吩[2,3‑d]嘧啶酮苯磺酰胺类衍生物及用途 | |
CN103588758A (zh) | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 | |
CN105541834B (zh) | 一种2‑苯基咪唑并[1,2‑a]吡啶类化合物的合成方法 | |
CN104725393B (zh) | 一种岩白菜素的衍生物、制备方法及应用 | |
CN102731493A (zh) | 一类抗肿瘤含苯并噻唑杂环结构的化合物及其应用 | |
CN103664786A (zh) | 一类水杨醛的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN102675205B (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN108997319B (zh) | 硫代咪唑烷酮衍生物及其合成方法与应用 | |
CN104586842B (zh) | 一种抗癌活性吲哚衍生物、合成方法及其用途 | |
CN103073606B (zh) | 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法 | |
CN104910075B (zh) | 一种双吡唑希夫碱化合物及其制备方法及其作为杀菌剂的应用 | |
CN104945388A (zh) | 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用 | |
CN104230904A (zh) | 一类含萘环骨架的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用 | |
CN112194660B (zh) | 一种pde2抑制剂苯基吡唑并嘧啶类化合物及其制备方法 | |
CN104447705A (zh) | 一类含1-吲哚乙酸-5-硝基咪唑衍生物的合成及其生物活性评价 | |
CN108033913A (zh) | 一种二氢吡唑啉衍生物及其制备方法和应用 | |
CN104829534A (zh) | 一类含萘环骨架的二氢吡唑吗啉衍生物的制备方法及在抗癌药物中的应用 | |
CN105461723A (zh) | 酞嗪并[1,2,b]喹唑啉-8-酮化合物及其制备方法和在抗肿瘤药物中的应用 | |
CN106946974B (zh) | 一类含吡唑杂环的熊果酰胺衍生物及其合成与应用 | |
CN101812072B (zh) | 一种抗血小板聚集化合物的制备方法 | |
CN105859618B (zh) | 含环烷基腈基团的异喹啉‑1,3(2h,4h)‑二酮及其制法和用途 | |
CN109305961A (zh) | 具有药物活性的伊马胺衍生物及其制备方法 | |
CN107382867A (zh) | 4‑异硫氰酸酯基吡唑啉酮类化合物 | |
CN104974217A (zh) | 一类脱氢枞酸喹喔啉衍生物及其制备方法和应用 | |
CN103059001B (zh) | 一种含三氮唑的喹唑啉酮席夫碱及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140219 |